Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

被引:110
作者
Nowicki, M. [2 ]
Rychlik, I. [3 ]
Haller, H. [4 ]
Warren, M. [5 ]
Suchower, L. [6 ]
Gause-Nilsson, I. [1 ]
Schutzer, K-M. [1 ]
机构
[1] AstraZeneca R&D, S-43183 Molndal, Sweden
[2] Med Univ Lodz, Lodz, Poland
[3] Charles Univ Prague, Sch Med 3, Prague, Czech Republic
[4] Hannover Med Sch, D-30623 Hannover, Germany
[5] Phys E PA, Greenville, NC USA
[6] AstraZeneca LP, Wilmington, DE USA
关键词
IMPROVES GLYCEMIC CONTROL; METFORMIN; HYPOGLYCEMIA; THERAPY; SULFONYLUREA; COMBINATION; GLIPIZIDE;
D O I
10.1111/j.1742-1241.2011.02812.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Therapeutic options are limited for diabetes patients with renal disease. This report presents 52-week results from a study assessing the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Design: Double-blind study in patients stratified by baseline renal impairment (moderate, severe or end-stage renal disease [ESRD] on haemodialysis) randomised to saxagliptin 2.5 mg once daily or placebo added to other antidiabetic drugs in use at baseline, including insulin. Patients: A total of 170 adults with glycated haemoglobin (HbA(1c)) 7-11% and creatinine clearance <50 ml/min or ESRD were randomised and treated. Measurements: Absolute changes in HbA1c and fasting plasma glucose (FPG) from baseline to week 52 were evaluated using analysis of covariance (ANCOVA) with last observation carried forward. Repeated-measures analyses were also performed. Results: Adjusted mean decrease in HbA1c was greater with saxagliptin than placebo (difference,) -0.73%, p < 0.001 [ANCOVA]). Reductions in adjusted mean HbA1c were numerically greater with saxagliptin than placebo in patients with renal impairment rated as moderate ( -0.94% vs. 0.19% respectively) or severe (-0.81% vs. -0.49%), but similar to placebo for those with ESRD (-1.13% vs. -0.99%). Reductions in adjusted mean FPG were numerically greater with saxagliptin in patients with moderate or severe renal impairment. Saxagliptin was generally well tolerated; similar proportions of patients in the saxagliptin and placebo groups reported hypoglycaemic events (28% and 29% respectively). Conclusions: Saxagliptin 2.5 mg once daily offers sustained efficacy and good tolerability for patients with T2DM and renal impairment.
引用
收藏
页码:1230 / 1239
页数:10
相关论文
共 38 条
[1]  
[Anonymous], NOT GUID EV PHARM ME
[2]  
[Anonymous], 1998, PHARM PAT IMP REN FU
[3]  
[Anonymous], ONGL SAX
[4]  
[Anonymous], 2009, Glucophage and Glucophage XR: Highlights of prescribing information
[5]   Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin [J].
Boulton, David W. ;
Li, Li ;
Frevert, Ernst U. ;
Tang, Angela ;
Castaneda, Lorna ;
Vachharajani, Nimish N. ;
Kornhauser, David M. ;
Patel, Chirag G. .
CLINICAL PHARMACOKINETICS, 2011, 50 (04) :253-265
[6]   Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial [J].
Chacra, A. R. ;
Tan, G. H. ;
Apanovitch, A. ;
Ravichandran, S. ;
List, J. ;
Chen, R. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) :1395-1406
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study [J].
Davis, Timothy M. E. ;
Brown, Simon G. A. ;
Jacobs, Ian G. ;
Bulsara, Max ;
Bruce, David G. ;
Davis, Wendy A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) :2240-2247
[9]   The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone [J].
DeFronzo, Ralph A. ;
Hissa, Miguel N. ;
Garber, Alan J. ;
Gross, Jorge Luiz ;
Duan, Raina Yuyan ;
Ravichandran, Shoba ;
Chen, Roland S. .
DIABETES CARE, 2009, 32 (09) :1649-1655
[10]  
Defronzo RA, 2009, DIABETES, V58, pA147